HIV Drug Buyers Want Gilead Product Switch Claims Revived

By Bryan Koenig · November 12, 2024, 9:19 PM EST

Insurers and benefit plans are asking the Ninth Circuit to revive a chunk of their antitrust case against Gilead, arguing their claims that Gilead delayed generic competition to its HIV drugs...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019

Case Title

United Healthcare Services, Inc. v. Gilead Sciences, Inc., et al.

Case Number

Court

Appellate - 9th Circuit

Nature of Suit

Date Filed

March 18, 2024

Recent Articles By Bryan

November 15, 2024
PBMs Denied Breakup Of Combined FTC Insulin Price Trial
November 13, 2024
Outgoing DOJ Antitrust Head Wants To Unstack Healthcare
November 12, 2024
Unsatisfied With $70M UTC Win, Sandoz Appeals To 3rd Circ.
November 07, 2024
Same PBM Conduct Means Same Insulin Price Trial, FTC Says
October 21, 2024
PBMs Keep Door Open To Constitutional Riposte Against FTC
October 16, 2024
Caremark, Optum Say FTC Insulin Case Gets PBMs All Wrong
October 15, 2024
'Extraordinary' Blue Cross Deal Includes $2.8B Payout
October 07, 2024
Merck Immune For 'Inflated' Vax Claims To FDA, 3rd Circ. Says
September 06, 2024
Actelion Must Face Tracleer Antitrust Suit With Class Certified
August 28, 2024
Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit